Literature DB >> 26826442

Antibody therapeutics for Ebola virus disease.

Larry Zeitlin1, Kevin J Whaley2, Gene G Olinger3, Michael Jacobs4, Robin Gopal5, Xiangguo Qiu6, Gary P Kobinger7.   

Abstract

With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26826442      PMCID： PMC4902774          DOI： 10.1016/j.coviro.2016.01.006

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN： 1879-6257            Impact factor:   7.090


  29 in total

1.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

3.  Evaluating Ebola therapies--the case for RCTs.

Authors:  Edward Cox; Luciana Borio; Robert Temple
Journal:  N Engl J Med       Date:  2014-12-03       Impact factor: 91.245

4.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Authors:  Gene Garrard Olinger; James Pettitt; Do Kim; Cara Working; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael Pauly; Kevin J Whaley; Calli M Lear; Julia E Biggins; Corinne Scully; Lisa Hensley; Larry Zeitlin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

5.  Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Authors:  James Pettitt; Larry Zeitlin; Do H Kim; Cara Working; Joshua C Johnson; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael H Pauly; Kevin J Whaley; Michael F Ingram; Ashley Zovanyi; Megan Heinrich; Ashley Piper; Justine Zelko; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

6.  Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.

Authors:  Peter B Jahrling; Joan B Geisbert; James R Swearengen; Thomas Larsen; Thomas W Geisbert
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

Review 7.  Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.

Authors:  L Zeitlin; R A Cone; K J Whaley
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

8.  Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys.

Authors:  Wendelien B Oswald; Thomas W Geisbert; Kelly J Davis; Joan B Geisbert; Nancy J Sullivan; Peter B Jahrling; Paul W H I Parren; Dennis R Burton
Journal:  PLoS Pathog       Date:  2007-01       Impact factor: 6.823

9.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

Review 10.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Authors:  Nancy J Sullivan; Julie E Martin; Barney S Graham; Gary J Nabel
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633
View more
  21 in total

Review 1.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 2.  Immune barriers of Ebola virus infection.

Authors:  Anita K McElroy; Elke Mühlberger; César Muñoz-Fontela
Journal:  Curr Opin Virol       Date:  2018-02-16       Impact factor: 7.090

Review 3.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

Review 4.  Therapeutic strategies to target the Ebola virus life cycle.

Authors:  Thomas Hoenen; Allison Groseth; Heinz Feldmann
Journal:  Nat Rev Microbiol       Date:  2019-07-24       Impact factor: 60.633

Review 5.  Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development.

Authors:  Rejane L Petersen
Journal:  Biosensors (Basel)       Date:  2017-10-31

6.  The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.

Authors:  Elizabeth A Nelson; Julie Dyall; Thomas Hoenen; Alyson B Barnes; Huanying Zhou; Janie Y Liang; Julia Michelotti; William H Dewey; Lisa Evans DeWald; Richard S Bennett; Patrick J Morris; Rajarshi Guha; Carleen Klumpp-Thomas; Crystal McKnight; Yu-Chi Chen; Xin Xu; Amy Wang; Emma Hughes; Scott Martin; Craig Thomas; Peter B Jahrling; Lisa E Hensley; Gene G Olinger; Judith M White
Journal:  PLoS Negl Trop Dis       Date:  2017-04-12

7.  Broad-Range Antiviral Activity of Hydrogen Sulfide Against Highly Pathogenic RNA Viruses.

Authors:  Nikolay Bazhanov; Olivier Escaffre; Alexander N Freiberg; Roberto P Garofalo; Antonella Casola
Journal:  Sci Rep       Date:  2017-01-20       Impact factor: 4.379

8.  Potent neutralizing monoclonal antibodies against Ebola virus infection.

Authors:  Qi Zhang; Miao Gui; Xuefeng Niu; Shihua He; Ruoke Wang; Yupeng Feng; Andrea Kroeker; Yanan Zuo; Hua Wang; Ying Wang; Jiade Li; Chufang Li; Yi Shi; Xuanling Shi; George F Gao; Ye Xiang; Xiangguo Qiu; Ling Chen; Linqi Zhang
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

9.  Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: A cross-sectional study.

Authors:  Catherine F Houlihan; Catherine R McGowan; Steve Dicks; Marc Baguelin; David A J Moore; David Mabey; Chrissy H Roberts; Alex Kumar; Dhan Samuel; Richard Tedder; Judith R Glynn
Journal:  PLoS Med       Date:  2017-05-16       Impact factor: 11.069

Review 10.  Ebola virus disease: an update on post-exposure prophylaxis.

Authors:  William A Fischer; Pauline Vetter; Daniel G Bausch; Timothy Burgess; Richard T Davey; Robert Fowler; Frederick G Hayden; Peter B Jahrling; Andre C Kalil; Douglas L Mayers; Aneesh K Mehta; Timothy M Uyeki; Michael Jacobs
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.